<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
    <link rel="stylesheet" href="../css/uswds.min.css">
    <link rel="stylesheet" href="../css/style.css">
    <link rel="stylesheet" href="css/uswds.min.css">
    <link rel="stylesheet" href="css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title40.html">
                                    Title 40
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/40CFR180.html">Part 180
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 180.611  Pinoxaden; tolerances for residues.
                            </h3>
                            <p class="depth0"><em>(a)</em> General. (1) Tolerances are established for the combined residues of pinoxaden (8-(2,6-diethyl-4-methylphenyl)-1,2,4,5-tetrahydro-7-oxo-7H-pyrazolo[1,2-d][1,4,5] oxadiazepin-9-yl 2,2-dimethylpropanoate), and its metabolites 8-(2,6-diethyl-4-methyl-phenyl)-tetrahydro-pyrazolo[1,2-d][1,4,5]oxadiazepine-7,9-dione (M2), and free and conjugated forms of 8-(2,6-diethyl-4-hydroxymethyl-phenyl)-tetrahydro-pyrazolo[1,2-d][1,4,5] oxadiazepine-7,9-dione (M4), and 4-(7,9-dioxo-hexahydro-pyrazolo[1,2-d] [1,4,5]oxadiazepin-8-yl)-3,5-diethyl-benzoic acid (M6), calculated as pinoxaden, in/on the following commodities:
------------------------------------------------------------------------</p><p class="depth0">Parts per</p><p class="depth0">Commodity                             million------------------------------------------------------------------------Barley, bran................................................        1.6Barley, grain...............................................        0.9Barley, hay.................................................        1.5Barley, straw...............................................        1.0Egg.........................................................        0.06Poultry, fat................................................        0.06Poultry, meat...............................................        0.06Poultry, meat byproducts....................................        0.06Wheat, bran.................................................        3.0Wheat, forage...............................................        3.5Wheat, grain................................................        1.3Wheat, hay..................................................        2.0Wheat, straw................................................        1.5------------------------------------------------------------------------</p><p class="depth0"><em>(2)</em> For the combined residues of pinoxaden, 8-(2,6-diethyl-4-methylphenyl)-1,2,4,5-tetrahydro-7-oxo-7H-pyrazolo[1,2-d][1,4,5] oxadiazepin-9-yl 2,2-dimethylpropanoate), and its metabolites M2, 8-(2,6-diethyl-4-methyl-phenyl)-tetrahydro-pyrazolo[1,2-d][1,4,5]oxadiazepine-7,9-dione, and free and conjugated forms of M4, 8-(2,6-diethyl-4-hydroxymethyl-phenyl)-tetrahydro-pyrazolo[1,2-d][1,4,5] oxadiazepine-7,9-dione, calculated as pinoxaden, in/on the following commodities:
------------------------------------------------------------------------</p><p class="depth0">Parts per</p><p class="depth0">Commodity                             million------------------------------------------------------------------------Cattle, fat.................................................        0.04Cattle, meat................................................        0.04Cattle, meat byproducts.....................................        0.04Milk........................................................        0.02------------------------------------------------------------------------</p><p class="depth0"><em>(b)</em> Section 18 emergency exemptions. [Reserved]</p><p class="depth0"><em>(c)</em> Tolerances with regional registrations. [Reserved]</p><p class="depth0"><em>(d)</em> Indirect or inadvertent residues. [Reserved]
[70 FR 43322, July 27, 2005]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>. Code available <a href="#">on Github.</a></h5>
      </div>
    </div>
  </footer>
  </body>
</html>
